Investor Presentaiton
Financial Forecasts for FY2023
Revenue of Major Products in North America & China
Change
FY2022
Results
FY2023
Forecasts
Change
FY2022
Results
FY2023
Forecasts
Value
FX impact
%
North America
Million $
Billions of yen
ORGOVYXⓇ
182
396
214
24.7
51.5
26.8
(2.2)
MYFEMBREEⓇ
33
192
159
4.5
24.9
20.4 (1.1)
108.5
454.1
GEMTESAⓇ
182
362
180
24.7
47.0
22.3
(2.0)
90.5
APTIOMⓇ
249
273
24
33.7
35.5
1.8
(1.5)
5.3
RETHYMICⓇ
33
54
21
4.4
7.0
2.6
(0.3)
57.7
LATUDAⓇ
1,465
161 (1,304)
198.5
20.9 (177.6)
(0.9)
(89.5)
Others
280
167
(113)
38.0
22.0 (16.0)
(0.9)
(42.0)
Total
2,424
1,605
(819)
328.5
208.8 (119.7)
(8.8)
(36.4)
China
Million RMB
Billions of yen
MEROPENⓇ
1,445
958
(487)
28.5
18.7
(9.8)
(0.2)
(34.5)
Others
Total
550
737
187
10.9
14.3
3.4
1,995
1,695
(300)
39.4
33.0
(6.4)
(0.4)
(0.2) 31.6
(16.2)
* Lump-sum revenue included in "Others"
FY2022
Deferred revenue from the collaboration with Pfizer of $138M
Revenue from the license agreement for ORGOVYX® of $50M
FY2023
Deferred revenue from the collaboration with Pfizer of $117M
North America segment
Due to loss of exclusivity of LATUDAⓇ in
February 2023, revenue will decrease
significantly in FY2023
ORGOVYXⓇ and MYFEMBREEⓇ will
accelerate the efficiency of sales activities
with the acquisition of Myovant as a wholly
owned subsidiary
■GEMTESAⓇ is expected continued steady
growth
■ KYNMOBIⓇ and LONHALAⓇ MAGNAIRⓇ
have been decided to discontinue sales
China segment
Revenue of MEROPENⓇ will be expected
to decrease due to the growing impact of
Volume-Based Procurement application
FX rates:
FY2022 Results : 1US$ ¥135.51, 1RMB = \19.75
FY2023 Forecasts: 1US$ = ¥130.00, 1RMB = \19.50
© Sumitomo Pharma Co., Ltd. All Rights Reserved. 14View entire presentation